Because $999 May Not Keep Investors Happy

Nov 23, 2007

David Hamilton has an article at VentureBeat about how viable the business model behind companies like 23andMe will turn out to be.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Already have an account?
Login Now.

Breaking News

Luminex Receives FDA Clearance for C. Diff Assay
Top Five Articles on GenomeWeb Last Week: Dogs, Courtagen, Thermo Fisher, and More
Genetic Technologies Facing Nasdaq Delisting
Exosome Diagnostics Completes $30 Million Series C Financing
Researchers Find MRSA Genesis Occurred Years Before Clinical Introduction of Methicillin
In Brief This Week: Quest Diagnostics, Agilent Technologies, Meridian Bioscience, and More

The Scan

Drive Resistance

Gene drives might run into biological resistance, the Economist reports.

Dalí DNA Collected

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Synthetic-Conservation Biology Disconnect

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

This Week in Science

In Science this week: full CRISPR locus integration complex structure, and more.

Main menu